Published in Rev Infect Dis on January 15, 1988
Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev (2005) 6.02
Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect Immun (1990) 2.89
Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun (1988) 2.55
Use of the promoter fusion transposon Tn5 lac to identify mutations in Bordetella pertussis vir-regulated genes. Infect Immun (1989) 2.40
Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol (2001) 2.02
Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg Infect Dis (2002) 1.58
The influence of social norms on the dynamics of vaccinating behaviour for paediatric infectious diseases. Proc Biol Sci (2014) 1.55
Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis. Infect Immun (1992) 1.52
Whooping cough--a continuing problem. BMJ (2002) 1.43
Pertussis--a disease and a vaccine that are not going away. West J Med (1989) 1.35
Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen. Infect Immun (1990) 1.19
Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect (1993) 1.08
Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev (2016) 1.07
Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro. Infect Immun (1991) 0.98
A model for estimating the impact of changes in children's vaccines. Am J Public Health (1995) 0.95
Outcomes of Bordetella infections in vaccinated children: effects of bacterial number in the nasopharynx and patient age. Clin Diagn Lab Immunol (1999) 0.93
Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role. Infect Immun (2002) 0.91
Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis. Infect Immun (1991) 0.90
Why the MRC randomized trials of whooping cough (pertussis) vaccines remain important more than half a century after they were done. J R Soc Med (2007) 0.90
Boosting understanding of pertussis outbreaks. Proc Natl Acad Sci U S A (2011) 0.86
Modelling heterogeneity and the impact of chemotherapy and vaccination against human hookworm. J R Soc Interface (2008) 0.86
Seroprevalence of Immunoglobulin G antibodies against pertussis toxin among asymptomatic medical students in the west of Iran: a cross sectional study. BMC Infect Dis (2009) 0.84
Construction of Bordetella pertussis strains that overproduce genetically inactivated pertussis toxin. Appl Environ Microbiol (1992) 0.84
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83
Bounded rationality alters the dynamics of paediatric immunization acceptance. Sci Rep (2015) 0.79
Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid. Infect Immun (1993) 0.78
Estimating vaccine efficacy under the heterogeneity of vaccine action in a nonrandomly mixing population. J Biopharm Stat (2013) 0.76
Statement on pertussis immunization. National Advisory Committee on Immunization. CMAJ (1993) 0.75
What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. Pathog Dis (2015) 0.75
Relationship of immunogenicity to protective potency in acellular pertussis vaccines. Hum Vaccin Immunother (2014) 0.75
Measles in England and Wales--I: An analysis of factors underlying seasonal patterns. Int J Epidemiol (1982) 5.16
The efficiency of measles and pertussis notification in England and Wales. Int J Epidemiol (1985) 3.64
Individual versus public priorities in the determination of optimal vaccination policies. Am J Epidemiol (1986) 2.55
Measles in England and Wales--II: The impact of the measles vaccination programme on the distribution of immunity in the population. Int J Epidemiol (1982) 2.16
The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet (1982) 2.05
Protective efficacy of BCG against leprosy in Northern Malawi. Lancet (1986) 1.48
Distribution of immunity to pertussis in the population of England and Wales. J Hyg (Lond) (1984) 1.24
Measles in England and Wales--III: Assessing published predictions of the impact of vaccination on incidence. Int J Epidemiol (1983) 1.19
Seroepidemiological studies of leprosy in northern Malawi based on an enzyme-linked immunosorbent assay using synthetic glycoconjugate antigen. Int J Lepr Other Mycobact Dis (1988) 1.16
Seasonal influences on pertussis. Int J Epidemiol (1986) 1.10
Delays in notification of infectious disease. Health Trends (1987) 1.04
The efficacy of pertussis vaccines under conditions of household exposure. Further analysis of the 1978-80 PHLS/ERL study in 21 area health authorities in England. Int J Epidemiol (1988) 0.93
Long term effects of exposure to viral infections in utero. Br Med J (Clin Res Ed) (1985) 0.81
A taste of success. J Pract Nurs (1981) 0.75
Confessions of a nursing instructor. J Nurs Educ (1983) 0.75
Expanding role of the LPN. J Pract Nurs (1982) 0.75